383 related articles for article (PubMed ID: 6170752)
1. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain.
Lappalainen J; Hietala J; Koulu M; Seppälä T; Sjöholm B; Syvälahti E
J Pharmacol Exp Ther; 1990 Feb; 252(2):845-52. PubMed ID: 2179533
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
4. Lasting changes in high affinity 3H-spiperone binding to the rat striatum and mesolimbic area after chronic methamphetamine administration: evaluation of dopaminergic and serotonergic receptor components.
Akiyama K; Sato M; Kashihara K; Otsuki S
Biol Psychiatry; 1982 Dec; 17(12):1389-402. PubMed ID: 7159638
[TBL] [Abstract][Full Text] [Related]
5. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
6. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
[TBL] [Abstract][Full Text] [Related]
7. [Effect of carbidine on the dopamine and serotonin receptors of the central nervous system].
Zharkovskiĭ AM; Klassen NE; Zharkovskiĭ TA
Biull Eksp Biol Med; 1985 Jun; 99(6):700-2. PubMed ID: 2861866
[TBL] [Abstract][Full Text] [Related]
8. [The affinity of aromatic fluoride derivatives of phenothiazine neuroleptics to spiroperidol binding sites of dopamine receptors by the radioligand technic in vitro].
Oelssner W; Peinhardt G; Büge A
Pharmazie; 1985 May; 40(5):341-2. PubMed ID: 2863832
[TBL] [Abstract][Full Text] [Related]
9. Acute and subchronic effects of MJ-13859, a potential antipsychotic drug, on rat brain dopaminergic function.
McMillen BA
J Pharmacol Exp Ther; 1985 May; 233(2):369-75. PubMed ID: 2987476
[TBL] [Abstract][Full Text] [Related]
10. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
[TBL] [Abstract][Full Text] [Related]
11. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
Altar CA; Kim H; Marshall JF
J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
[TBL] [Abstract][Full Text] [Related]
12. The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain.
Rosenfeld MR; Makman MH
J Pharmacol Exp Ther; 1981 Mar; 216(3):526-31. PubMed ID: 7205633
[TBL] [Abstract][Full Text] [Related]
13. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
16. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
17. Effect of pyridoxine deficiency in young rats on high-affinity serotonin and dopamine receptors.
Paulose CS; Dakshinamurti K
J Neurosci Res; 1985; 14(2):263-70. PubMed ID: 4046074
[TBL] [Abstract][Full Text] [Related]
18. Brain neurotransmitter receptor alterations in offspring of rats exposed to phenobarbital, phenytoin or their combination during pregnancy.
Seth PK; Alleva FR; Takagi S; Yen-Koo HC; Balazs T
Neurotoxicology; 1987; 8(1):45-53. PubMed ID: 3031564
[TBL] [Abstract][Full Text] [Related]
19. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
Matthews RT; McMillen BA; Sallis R; Blair D
J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
[TBL] [Abstract][Full Text] [Related]
20. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
Meltzer HY; Matsubara S; Lee JC
Psychopharmacol Bull; 1989; 25(3):390-2. PubMed ID: 2576319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
